NASDAQ:BLU

BELLUS Health - BLU Stock Forecast, Price & News

$9.83

+0.12 (+1.24%)

(As of 12/8/2022 02:43 PM ET)

Add

Compare

Today's Range: $9.72
▼
$9.94
50-Day Range: $8.59
▼
$10.76
52-Week Range: $4.98
▼
$12.69

Volume: 10,307 shs
Average Volume: 604,914 shs
Market Capitalization: $1.24 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

BELLUS Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 103.5% Upside
$20.00 Price Target
Short Interest: Bearish
7.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.74) to ($0.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

499th out of 1,022 stocks

Pharmaceutical Preparations Industry

221st out of 499 stocks

3.5

Analyst's Opinion

Consensus Rating
BELLUS Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, BELLUS Health has a forecasted upside of 103.5% from its current price of $9.83.
Amount of Analyst Coverage
BELLUS Health has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.88% of the outstanding shares of BELLUS Health have been sold short.
Short Interest Ratio / Days to Cover
BELLUS Health has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.
Change versus previous month
Short interest in BELLUS Health has recently decreased by 13.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BELLUS Health does not currently pay a dividend.
Dividend Growth
BELLUS Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLU.

3.2

News and Social Media Coverage

News Sentiment
BELLUS Health has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BELLUS Health this week, compared to 1 article on an average week.
Search Interest
4 people have searched for BLU on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BELLUS Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.17% of the stock of BELLUS Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.64% of the stock of BELLUS Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for BELLUS Health are expected to decrease in the coming year, from ($0.74) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BELLUS Health is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BELLUS Health is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BELLUS Health has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BELLUS Health (NASDAQ:BLU) Stock

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

November 16, 2022 | markets.businessinsider.com

RBC Capital Keeps Their Buy Rating on BELLUS Health (BLU)

October 19, 2022 | markets.businessinsider.com

TSX Ends Lower As Inflation Data Fuels Interest Rate Concerns

September 30, 2022 | markets.businessinsider.com

Expert Ratings for BELLUS Health

September 7, 2022 | seekingalpha.com

Bellus: Expected Phase 3 Start Makes This A Long-Term Play

August 22, 2022 | finance.yahoo.com

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

August 2, 2022 | theglobeandmail.com

Bellus Health Inc stock raised on Friday.

July 14, 2022 | finance.yahoo.com

Why BELLUS Health Stock Fell Today

July 14, 2022 | markets.businessinsider.com

Here's Why BELLUS Health Shares Are Diving Lower Today

July 14, 2022 | markets.businessinsider.com

Bellus Health Prices Public Offering Of 16.54 Mln Shares At US$9.25/shr

July 14, 2022 | finance.yahoo.com

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

July 13, 2022 | seekingalpha.com

RBC Capital Markets reiterates outperform rating, ups price target on BELLUS Health

July 6, 2022 | baystreet.ca

BELLUS, Dollarama, Loblaw at 52-Week Highs

July 5, 2022 | ca.finance.yahoo.com

Parabolic Returns in 2022 Are Possible From 3 Growth Stocks

July 5, 2022 | finance.yahoo.com

BELLUS Health to Participate in the William Blair Biotech Focus Conference

July 2, 2022 | nasdaq.com

Zacks Investment Ideas feature highlights: Bellus Health

June 28, 2022 | nasdaq.com

Here's Why Bellus Health (BLU) is a Great Momentum Stock to Buy

June 13, 2022 | finance.yahoo.com

Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health

June 10, 2022 | finance.yahoo.com

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

June 9, 2022 | finance.yahoo.com

Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation

June 7, 2022 | finance.yahoo.com

Are Medical Stocks Lagging Bellus Health (BLU) This Year?

June 6, 2022 | nasdaq.com

Wall Street Analysts See an 83% Upside in Bellus (BLU): Can the Stock Really Move This High?

May 18, 2022 | nasdaq.com

Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?

May 17, 2022 | nasdaq.com

Wall Street Analysts Believe Bellus (BLU) Could Rally 32%: Here's is How to Trade

May 11, 2022 | finance.yahoo.com

BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

April 25, 2022 | finance.yahoo.com

BELLUS Health to Participate in Multiple Upcoming Investor Conferences

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Company Calendar

Last Earnings: 11/10/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLU
CUSIP: N/A
CIK: 1259942
Web: www.bellushealth.com
Phone: (450) 680-4500
Fax: 45-0680-4501
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $20.00
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +103.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,220,000.00
Net Margins: -453,737.50%
Pretax Margin: -454,725.00%
Return on Equity: -23.37%
Return on Assets: -22.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.96
Quick Ratio: 16.96

Sales & Book Value

Annual Sales: $20,000.00
Price / Sales: 61,825.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.74 per share
Price / Book: 3.59

Miscellaneous

Outstanding Shares: 125,790,000
Free Float: 95,389,000
Market Cap: $1.24 billion
Optionable: Not Optionable
Beta: 0.08

Key Executives

Mr. Roberto Francesco Bellini (Age 42)
Pres, CEO & Director
Comp: $353.03k

Mr. Ramzi Benamar (Age 49)
Chief Financial Officer
Comp: $607.33k

Dr. Denis Garceau (Age 65)
Chief Scientific Officer
Comp: $431.87k

Mr. Tony Matzouranis (Age 49)
Sr. VP of Bus. Devel.
Comp: $272.89k

Dr. Catherine M. Bonuccelli M.D. (Age 64)
Chief Medical Officer
Comp: $703.77k

Dr. Andreas Orfanos FFPM (Age 63)
M.B.B.Ch, MBA, Chief Operating Officer

Mr. Daniel Matthews
Director of Investor Relations & Communications

Mr. Francois Desjardins C.A. (Age 59)
CPA, CPA, CA, Sr. VP of Fin.

Mr. Sebastien Roy (Age 46)
Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLU Stock - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLU shares.
View BLU analyst ratings or view top-rated stocks.
What is BELLUS Health's stock price forecast for 2023?: 5 Wall Street analysts have issued twelve-month price objectives for BELLUS Health's shares. Their BLU share price forecasts range from $18.00 to $21.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for BLU or view top-rated stocks among Wall Street analysts.
How have BLU shares performed in 2022?: BELLUS Health's stock was trading at $8.05 at the beginning of 2022. Since then, BLU stock has increased by 21.4% and is now trading at $9.77.
View the best growth stocks for 2022 here.
Are investors shorting BELLUS Health?: BELLUS Health saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,910,000 shares, a drop of 13.1% from the October 31st total of 11,410,000 shares. Based on an average trading volume of 610,200 shares, the days-to-cover ratio is currently 16.2 days.
View BELLUS Health's Short Interest.
When is BELLUS Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BLU earnings forecast.
How were BELLUS Health's earnings last quarter?: BELLUS Health Inc. (NASDAQ:BLU) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative net margin of 453,737.50% and a negative trailing twelve-month return on equity of 23.37%.

What other stocks do shareholders of BELLUS Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).
What is BELLUS Health's stock symbol?: BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."
Who are BELLUS Health's major shareholders?: BELLUS Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.05%), Perceptive Advisors LLC (8.15%), Pictet Asset Management SA (6.65%), Commodore Capital LP (4.08%), Lynx1 Capital Management LP (1.89%) and First Light Asset Management LLC (1.89%).
How do I buy shares of BELLUS Health?: Shares of BLU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BELLUS Health's stock price today?: One share of BLU stock can currently be purchased for approximately $9.77.
How much money does BELLUS Health make?: BELLUS Health (NASDAQ:BLU) has a market capitalization of $1.23 billion and generates $20,000.00 in revenue each year. The company earns $-71,220,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How can I contact BELLUS Health?: BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The official website for the company is www.bellushealth.com. The company can be reached via phone at (450) 680-4500, via email at fdesjardins@bellushealth.com, or via fax at 45-0680-4501.

This page (NASDAQ:BLU) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial